Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 27Lymphoid 10Thoracic 7Gynecologic 5Classical hematology 4Gastrointestinal 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × pegfilgrastim × Tumor-Agnostic × Clear all
NCT01214629 2018-08-06

A Study for Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
54 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01214642 2018-08-06

A Dose-Escalation Study for Patients With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
63 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡